A CAR-T Win for Celgene (CELG) as Partner bluebird bio Releases 'Highly Promising' Results - Jefferies
Get Alerts CELG Hot Sheet
Rating Summary:
7 Buy, 27 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 9 | New: 13
Join SI Premium – FREE
Jefferies analyst Brian Abrahams weighed in on Celgene (NASDAQ: CELG) after partner bluebird bio posted 'highly promising' bb2121 results in multiple myeloma.
Abrahams commented, "Data emerging from BLUE’s bb2121 (CELG-partnered) looks highly promising; though it will need to be replicated in a much broader pop., safety needs to stay clean, and durability and manufacturing/cost feasibility are unknowns with the approach, we believe it provides strong validation for CELG’s anti-BCMA candidates, helps offset recent BD/pipeline skepticism, and supports CELG’s underappreciated, multi-faceted MM life cycle extension strategy. "
The firm maintained a Buy rating and price target of $140 on BLUE.
For an analyst ratings summary and ratings history on Celgene click here. For more ratings news on Celgene click here.
Shares of Celgene closed at $118.51 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Northwest Bancshares, Inc. (NWBI) PT Lowered to $10 at Piper Sandler
- AZZ Inc. (AZZ) PT Raised to $85 at B.Riley
- Roth/MKM Upgrades Albertsons Companies Inc. (ACI) to Buy, 'Fundamental Floor and Improved Deal Likelihood'
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Jefferies & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!